

1 **SARS-CoV-2 booster vaccination rescues attenuated IgG1 memory B** 2 **cell response in primary antibody deficiency patients**

3
4 Frank J. Lin^{1,9}, Alexa Michelle Altman Doss^{2,9}, Hannah G. Davis-Adams¹, Lucas J. Adams³,
5 Christopher H. Hanson¹, Laura A. VanBlargan¹, Chieh-Yu Liang^{1,3}, Rita. E. Chen^{1,3}, Jennifer Marie
6 Monroy¹, H. James Wedner¹, Anthony Kulczycki¹, Tarisa L. Mantia¹, Caitlin C. O’Shaughnessy¹,
7 Saravanan Raju³, Fang R. Zhao¹, Elise Rizzi¹, Christopher J. Rigell¹, Tiffany Bason Dy¹, Andrew
8 L. Kau^{1,4}, Zhen Ren¹, Jackson Turner³, Jane A. O’Halloran¹, Rachel M. Presti^{1, 6}, Daved H.
9 Fremont³, Peggy L. Kendall¹, Ali H. Ellebedy^{3, 5, 6}, Philip A. Mudd^{6, 8}, Michael S. Diamond^{1,3,5,6, 7},
10 Ofer Zimmerman^{*1}, and Brian J. Laidlaw^{*1}

11 12 13 **Affiliations:**

14 ¹ Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.

15 ² Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, USA.

16 ³ Department of Pathology and Immunology, Washington University School of Medicine, St. Louis,
17 MO, USA.

18 ⁴ Center for Women’s Infectious Disease Research, Washington University School of Medicine,
19 St. Louis, MO, USA.

20 ⁵ The Andrew M. and Jane M. Bursky Center for Human Immunology & Immunotherapy
21 Programs, Washington University School of Medicine, Saint Louis, MO, USA.

22 ⁶ Center for Vaccines and Immunity to Microbial Pathogens, Washington University School of
23 Medicine, Saint Louis, MO, USA.

24 ⁷ Department of Molecular Microbiology, Washington University School of Medicine, St. Louis,
25 MO, USA.

26 ⁸ Department of Emergency Medicine, Washington University School of Medicine, St. Louis, MO,
27 USA.

28 ⁹ These authors contributed equally

29
30 * Correspondence should be addressed to Brian Laidlaw (brian.laidlaw@wustl.edu) and Ofer
31 Zimmerman (zimmero@wustl.edu)

32

33 **ABSTRACT**

34 SARS-CoV-2 vaccines have proven effective in eliciting an immune response capable of providing
35 protective immunity in healthy individuals. However, whether SARS-CoV-2 vaccination induces a
36 long-lived immune response in immunocompromised individuals is poorly understood. Primary
37 antibody deficiency (PAD) syndromes are among the most common immunodeficiency disorders
38 in adults and are characterized by an impaired ability to mount robust antibody responses
39 following infection or vaccination. Here, we present data from a prospective study in which we
40 analyzed the B and T cell response in PAD patients following SARS-COV-2 vaccination.
41 Unexpectedly, individuals with PAD syndromes mounted a SARS-CoV-2 specific B and CD4⁺ T
42 cell response that was comparable in magnitude to healthy individuals. Many individuals with PAD
43 syndromes displayed reduced IgG1⁺ and CD11c⁺ memory B cell responses following the primary
44 vaccination series. However, the IgG1 class-switching defect was largely rescued following
45 mRNA booster vaccination. Boosting also elicited an increase in the SARS-CoV-2-specific B and
46 T cell response and the development of Omicron-specific memory B cells in COVID-19-naïve
47 PAD patients. Together, these data indicate that SARS-CoV-2 vaccines elicit memory B and T
48 cells in PAD patients that may contribute to long-term protective immunity.

49 INTRODUCTION

50 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of
51 COVID-19 and has infected more than 500 million individuals resulting in over 6 million deaths as
52 of June 2022. The mRNA-based Pfizer-BioNTech (BNT162b2) and Moderna (mRNA-1273) and
53 the vector-based Johnson & Johnson (Ad26.COV2.S) SARS-CoV-2 vaccines are approved for
54 use in the United States and have demonstrated efficacy in preventing symptomatic and
55 asymptomatic infection (1–7). Although SARS-CoV-2-specific antibody titers wane over time, a
56 durable cellular immune response is detectable for at least 6 months following completion of the
57 primary vaccination series (8). The administration of an mRNA booster vaccine dose leads to a
58 rapid increase in antibody titers and enables robust neutralization of viral variants, including
59 Omicron (B.1.1.529), which can evade immunity elicited by the primary vaccination (9–12).

60
61 Individuals with medical conditions that compromise their ability to mount immune responses,
62 such as primary and secondary immunodeficiencies, are at increased risk for severe illness and
63 death following SARS-CoV-2 infection (13, 14). Patients with primary and secondary
64 immunodeficiencies also have an impaired SARS-CoV-2-specific antibody response following a
65 primary vaccination series (15–24). Moderately or severely immunosuppressed patients are
66 recommended by the Centers for Disease Control and Prevention (CDC) to receive a third dose
67 as part of their primary series against SARS-CoV-2 and a fourth dose at least 3 months following
68 the completion of the primary vaccination series. Administration of booster doses leads to an
69 increased SARS-CoV-2-specific antibody response in immunocompromised individuals (17, 24).

70
71 Primary antibody deficiency (PAD) syndromes are the most common symptomatic primary
72 immunodeficiency in adults and are characterized by an impaired ability to mount an antibody
73 response following infection or vaccination (25). The etiology of PAD syndromes is unknown in
74 most patients, with only 25-35% of cases explained by inborn errors of immunity (26–30).
75 Individuals with PAD syndromes are at increased risk of recurrent and severe infections,
76 autoimmunity, allergic disease, and cancer (25). Most individuals with PAD syndromes receive
77 intravenous or subcutaneous immunoglobulin replacement therapy every 1 to 4 weeks to reduce
78 the frequency and severity of infections (31). However, immunoglobulin replacement therapy
79 consists of immunoglobulin donated up to one year earlier and is unlikely to contain high titers of
80 neutralizing antibodies specific for the strain of SARS-CoV-2 that is dominant at the time of
81 administration (24, 32, 33).

82

83 We previously found that COVID-19-naïve individuals with PAD syndromes had a reduced SARS-
84 CoV-2-specific antibody response following vaccination relative to healthy donors (24). The
85 administration of a booster vaccine dose increased the antibody response and led to the
86 development of antibodies with an enhanced ability to neutralize the Delta (B.1.617.2) and
87 Omicron variants (24). However, the total and neutralizing antibody titers markedly declined by
88 day 90 post-boost suggesting that the endogenous antibody response may be insufficient to
89 mediate long-term protective immunity in individuals with PAD syndromes (24). In this study, we
90 performed a prospective analysis of the SARS-CoV-2-specific B and T cell response following
91 SARS-CoV-2 primary and booster vaccination in PAD patients. Unexpectedly, we found that most
92 individuals with PAD syndromes generated a memory B and T cell response that was comparable
93 in magnitude to the response in healthy donors following the primary vaccination series.
94 Administration of a booster dose led to a further enhancement in B and T cell responses, including
95 the development of Omicron-specific B cells. This work provides important insight into the
96 capacity of memory B and T cells to contribute to protective immunity in PAD patients.

97

98 **RESULTS**

99 **Individuals with PAD syndromes display a similar memory B cell response to healthy**
100 **controls following primary vaccination series.** We assessed the SARS-CoV-2-specific B and
101 CD4⁺ T cell response following vaccination in peripheral blood mononuclear cells (PBMCs) from
102 a cohort of 30 individuals with PAD syndrome (n=20 common variable immunodeficiency (CVID),
103 n=4 hypogammaglobulinemia, n=6 specific antibody deficiency) (**Fig. 1a, Table S1**). This cohort
104 completed their primary vaccination series (n=19 Pfizer-BioNTech BNT162b2, n=8 Moderna
105 mRNA-1273, n=3 J&J Ad26.COV2.S) with 9 of these individuals having a real time-polymerase
106 chain reaction (RT-PCR)-confirmed history of prior COVID-19 infection that occurred 36 to 276
107 days prior to vaccination. 19 of these individuals subsequently received a booster vaccine dose
108 (n=16 BNT162b2, n=3 mRNA-1273). PBMCs were obtained from these individuals at multiple
109 time points following completion of the primary vaccine series or the booster vaccine dose.
110 PBMCs also were obtained from a separate cohort of 11 COVID-19-naïve healthy donors
111 following completion of the primary vaccination series (n=11 BNT162b2) (**Table S1**). We then
112 used flow cytometry to assess the immune cell response in PBMCs following SARS-CoV-2
113 vaccination (**Fig. 1b, S1a, Table S2**). PAD patients had a reduced percentage of B and T cells
114 relative to healthy donors (**Fig. S1b, c, Table S2**). However, there was no difference in the
115 percentage of B cells that were IgD^{lo} or IgD^{lo}CD27⁺ or in the ratio of CD4⁺ to CD8⁺ cells among

116 the T cell population (**Fig. S1b, c, Table S2**). 29 out of 30 PAD patients had an absolute
117 lymphocyte count within the normal range on their most recent complete blood count (**Table S3**).

118
119 We then used His-tagged spike and RBD-binding probes to identify SARS-CoV-2-specific B cells
120 (34, 35). We found that 25 of 29 (86%) PAD patients with available samples had a detectable
121 spike and receptor binding domain (RBD)-specific IgD^{lo} B cell response following vaccination (**Fig.**
122 **1c, S2a**). Unexpectedly, we found that most COVID-19-naïve PAD patients displayed a
123 comparable SARS-CoV-2-specific B cell response to COVID-19-healthy donors at all time points
124 (**Fig. 1c, S2a**). The four PAD patients that did not respond to vaccination had a reduced
125 percentage of B cells that were IgD^{lo} and IgD^{lo} CD27⁺ and had a reduced neutralizing antibody
126 titer against the WA1/2020 and B.1.617.2 viruses following vaccination compared to responding
127 PAD patients (**Fig. S1b, d, Table S2**). COVID-19-experienced individuals with PAD syndrome
128 displayed a greater SARS-CoV-2 specific B cell response at day 7 to 28 following vaccination
129 relative to both healthy donor and COVID-19 naïve PAD patients, before declining to a
130 comparable level to the other 2 groups by day 60 (**Fig. 1c, S2a**). The SARS-CoV-2-specific
131 response amongst the activated B cell (IgD^{lo} CD20⁺ CD38^{int-lo}) population was divided between
132 conventional (CD27⁺) and double negative (CD27⁻) memory B cells, with both populations
133 displaying similar kinetics in COVID-19-naïve PAD patients and healthy donors (**Fig. 1d, e, S2b,**
134 **c**). Double negative B cells accumulate in individuals with chronic infection or autoimmunity, but
135 also are induced following vaccination in healthy individuals (36, 37). There was also a small
136 population of SARS-CoV-2-specific B cells detected amongst the non-class-switched memory
137 (IgD⁺ CD27⁺) B cell population following vaccination, with this population declining to baseline
138 levels by day 150 in all groups (**Fig. 1f, S2d**). Together, these data indicate that most individuals
139 with PAD syndromes can induce a comparable B cell response following SARS-CoV-2
140 vaccination to healthy donors, and that prior exposure to COVID-19 leads to a greater response
141 upon vaccination in PAD patients.

142
143 **COVID-19-naïve individuals with PAD syndrome have a robust B cell response following**
144 **booster vaccination.** We next evaluated the B cell response following booster vaccination in
145 individuals with PAD syndromes. Most COVID-19-naïve individuals with PAD syndromes
146 mounted a SARS-CoV-2-specific B cell response at day 7-28 following booster vaccination, with
147 an elevated percentage of cells present at day 150 following boosting compared to pre-boost
148 levels (**Fig. 2a, S3a**). However, there was minimal increase in the SARS-CoV-2-specific B cell
149 response in COVID-experienced PAD patients following boosting (**Fig. 2a-d, S3a-d**). The SARS-

150 CoV-2-specific B cell response following boosting was largely composed of conventional memory
151 and double negative B cells (**Fig. 2b-d, S3b-d**). While the percentage of SARS-CoV-2-specific
152 memory B cells prior to booster vaccination did not correlate with the titer of neutralizing antibodies
153 against the WA1/2020 and B.1.617.2 viruses, there was a correlation between the RBD-specific
154 memory B cell response and the neutralizing antibody titer against B.1.1.529 (**Fig. 2e-g**). This
155 suggests that SARS-CoV-2-specific memory B cells present in PAD individuals prior to booster
156 vaccination can give rise to antibody-secreting cells capable of neutralizing viral variants.

157
158 **Defect in IgG1 class-switching in memory B cells from COVID-19-naïve individuals with**
159 **PAD syndrome rescued following booster vaccination.** We next evaluated the isotype
160 specificity of the conventional memory B cell response following SARS-CoV-2 vaccination in 25
161 PAD patients that responded to vaccination (**Fig. 3a**). COVID-19-naïve individuals with PAD
162 syndromes had a reduced percentage of IgG1⁺ memory B cells relative to healthy donors at day
163 7 to 28 post vaccination, with these individuals also displaying an elevated percentage of IgM⁺
164 SARS-CoV-2-specific memory B cells (**Fig. 3b, c, S4a, b**). However, booster vaccination led to
165 an increase in the percentage of IgG1⁺ memory B cells in COVID-19-naïve PAD patients to levels
166 comparable to the healthy donors post vaccination (**Fig. 3b, S4a**). Booster vaccination also led to
167 a concomitant decrease in the percentage of IgM⁺ memory B cells (**Fig. 3c, S4b**). There was no
168 significant difference in the percentage of IgA⁺, IgG2⁺ or IgG3⁺ memory B cells between healthy
169 donors and COVID-19-naïve individuals (**Fig. 3d-f, S4c-e**). COVID-19-experienced individuals
170 with PAD syndromes displayed a similar memory B cell isotype composition to the healthy donor
171 cohort following the primary vaccination series (**Fig. 3, S4**). Together, these data indicate that the
172 repeated exposure to SARS-CoV-2 through vaccination and/or infection can rescue the defect in
173 IgG1-class switching seen in some individuals with PAD syndrome.

174
175 **Memory B cells from individuals with PAD syndrome display impaired CD11c expression**
176 **following vaccination.** We next assessed the phenotype of the SARS-CoV-2 specific
177 conventional memory B cell response post vaccination (**Fig. 4a, b**). We observed a marked
178 increase in the expression of CD11c on SARS-CoV-2-specific memory B cells at day 7 to 28
179 following vaccination in all groups, (**Fig. 4c, S5a**). CD11c expression is induced on B cells
180 following antigen encounter and therefore distinguishes recently activated cells. (38). There was
181 also an increase in the percentage of CD11c⁺ cells following boosting in the COVID-19-naïve PAD
182 syndrome group (**Fig. 4c, S5a**). However, even following an mRNA booster dose, CD11c
183 expression in COVID-19-naïve and experienced PAD patients was reduced relative to healthy

184 donors at day 7 to 28 post vaccination, suggesting that there is impaired B cell activation in some
185 individuals with PAD syndromes (39) (**Fig. 4c, S5a**). There was a significant correlation between
186 the percentage of CD11c⁺ and IgG1⁺ Spike⁺ memory B cells at day 7 to 28 post vaccination in
187 COVID-19-naïve PAD patients (**Fig. 4d, S5b**). CD11c expression can be induced on B cells by B
188 cell receptor (BCR) signaling (38). This suggests that the defect in IgG1 class switching seen in
189 some PAD patients may be related to impaired BCR signaling. However, there was no correlation
190 between the percentage of CD11c⁺ and IgG1⁺ CD27⁺ Spike⁺ memory B cells following boosting
191 indicating that repeated antigen exposure can rescue the defect in IgG1 class-switching despite
192 the reduction in B cell activation in many PAD patients (**Fig. 4d, S5b**). The percentage of CD11c⁺
193 memory B cells decreased by day 90 post vaccination or boosting, with this decrease
194 accompanied by a concomitant increase in the percentage of CXCR5⁺ memory B cells in all groups
195 (**Fig. 4c, e, S5a, b**).

196
197 We also determined the phenotype of the SARS-CoV-2 specific double negative B cell response
198 following vaccination (40). Double negative B cells can be divided into subsets based on
199 expression of CD11c and CXCR5 (40). There was an increased percentage of CD11c⁺ CXCR5⁻
200 (DN2) cells at day 7 to 28 post vaccination in all groups, with a higher increase in COVID-19
201 experienced PAD patients compared to COVID-19 naïve patients (**Fig. 4f, S5d**). A similar
202 increase was observed in both groups of individuals with PAD syndromes following boosting (**Fig.**
203 **4f, S5d**). Conversely, there was a decrease in the percentage of CD11c⁻ CXCR5⁺ (DN1) cells at
204 day 7 to 28 post vaccination in all groups, with this population returning to baseline at day 60 post
205 vaccination (**Fig. 4g, S5e**). A similar decrease in the percentage of DN1 cells also was apparent
206 following boosting in the PAD syndromes cohort (**Fig. 4f, S5d**). There was no clear difference in
207 the phenotype of the SARS-CoV-2-specific double negative memory B cells between the COVID-
208 19-naïve PAD individuals and the healthy donor group (**Fig. 4f, g, S5d, e**).

209
210
211 **Individuals with PAD syndrome display a robust SARS-CoV-2-specific CD4⁺ T cell**
212 **response following vaccination.** We next evaluated the T cell response following SARS-CoV-
213 2 vaccination (**Fig. 5a**). SARS-CoV-2-specific CD4⁺ T cells were identified using a S₁₆₇₋₁₈₀
214 tetramer, which binds an immunodominant SARS-CoV-2 spike epitope restricted by the HLA-
215 DPB1*04:01 allele that is found at >40% frequency in many populations around the world (41).
216 We also developed a S₈₁₆₋₈₃₀ tetramer that is specific for an immunodominant region of the S-II
217 portion of spike protein (42, 43). This region is highly conserved among coronaviruses and is also

218 restricted to the HLA-DPB1*4:01 allele (42). 16 out of 30 individuals with PAD syndromes and 4
219 out of 11 healthy donor samples had detectable SARS-CoV-2-specific CD4⁺ T cell responses.
220 COVID-naïve PAD patients displayed a similar percentage of SARS-CoV-2-specific CD4⁺ T cell
221 response as healthy donors at day 7 to 28 post vaccination before contracting by day 150 (**Fig.**
222 **5b-d**). Boosting led to an increase in the SARS-CoV-2-specific CD4⁺ T cell response (**Fig. 5b-d**).
223 COVID-experienced PAD patients had an increased percentage of SARS-CoV-2-specific CD4⁺ T
224 cell prior to vaccination relative to the other groups, consistent with a pre-existing memory
225 response (**Fig. 5b-d**). There was no correlation between the magnitude of the SARS-COV-2
226 specific CD4⁺ T cell response and the conventional memory B cell response following vaccination
227 in PAD patients (**Fig. 5e**). However, there was a strong correlation following boosting suggesting
228 that the pre-existing memory response in PAD patients can give rise to an enhanced B and T cell
229 response following antigen re-encounter (**Fig. 5f**).

230
231 **SARS-CoV-2-specific CD4⁺ T cells from PAD patients display a similar phenotype to cells**
232 **from healthy donors.** The phenotype of the SARS-CoV-2-specific CD4⁺ T cell response was
233 next assessed (**Fig. 6a, b**). SARS-CoV-2-specific CD4⁺ T cells adopted an activated phenotype
234 following vaccination and boosting in PAD patients, with this response characterized by increased
235 cell surface expression of PD1, ICOS, and CD38 (**Fig. 6c-e**). Expression of these markers was
236 similar between COVID-19-naïve individuals with PAD syndromes and healthy donors at day 7 to
237 28 following vaccination suggesting that there is no defect in CD4⁺ T cell activation in most
238 individuals with PAD syndromes (**Fig. 6c-e**). We also did not detect a difference in HLA-DR
239 expression between any of the groups (**Fig. 6f**). The phenotype of the CD4⁺ T cell response was
240 further assessed by determining the percentage of SARS-CoV-2-specific central
241 (CD45RO⁺CD27⁺CCR7⁺) and effector (CD45RO⁺CD27⁺CCR7⁺) memory CD4⁺ T cells (**Fig. 6g,**
242 **h**). We found there was no difference in the composition of the memory T cell response at T4
243 between the groups, suggesting that there also not a defect in the development of memory CD4⁺
244 T cells in PAD patients (**Fig. 6g, h**). Together, these data indicate that patients with PAD
245 syndromes exhibit a SARS-CoV-2-specific CD4⁺ T cell response that is similar in magnitude and
246 quality to the T cell response in healthy donors following vaccination.

247
248 **Booster vaccination induces Omicron-specific memory B cells in individuals with PAD**
249 **syndrome.** We assessed the Omicron-specific B cell response in individuals with PAD
250 syndromes using a His-tagged protein specific for the spike protein of B.1.1.529 (BA.1) (**Fig. 7a**).
251 We found that administration of a booster vaccine led to an increase in the percentage of Omicron

252 specific memory B cells in COVID-19-naïve individuals (**Fig. 7b**). This increase was evident in
253 both the conventional and double negative B cell populations (**Fig. 7c, d**). There was no increase
254 in the percentage of Omicron-specific non-class switched B cells (**Fig. 7e**). The percentage of
255 Omicron-specific B cell returned to pre-boost baseline level in most COVID-19-naïve individuals
256 by day 90 post boost (**Fig. 7b-d**). However, patient 110 displayed a robust increase in their
257 percentage of Omicron-specific B cell between B2 and B3, along with an increase in their SARS-
258 CoV-2-specific T cell response and neutralizing antibody titers. The B2 and B3 time points
259 correspond to the period between November 2021 and January 2022, when COVID-19 cases in
260 the United States surged due to the emergence of the Omicron variant. Patient 102 was confirmed
261 to have been re-infected between B2 and B3 and also displayed increased SARS-CoV-2-specific
262 T cell, B cell, and neutralizing antibody responses. Of note, patient 102 and 110 reported no or
263 very mild symptoms during this period.

264

265 **DISCUSSION**

266

267 In this study, we demonstrated that SARS-CoV-2 vaccination can induce a long-lived memory B
268 and CD4⁺ T cell response in individuals with PAD syndromes that is comparable to the response
269 seen in healthy donors. Furthermore, we found that the SARS-CoV-2-specific memory B cell
270 response correlated with neutralizing antibody titers against the Omicron variant following
271 boosting. Only 4 out of 29 patients did not develop a spike-specific memory B cell response
272 following vaccination with these individuals also having lower levels of memory B cells and
273 activated B cells compared to the other patients in the cohort. These results suggest that memory
274 B and T cells can promote long-term protective immunity in individuals with PAD syndromes
275 despite their impaired ability to mount optimal and sustained antibody responses following
276 infection and vaccination.

277

278 Despite the normal total memory B cell response in PAD patients in our cohort, SARS-CoV-2-
279 specific memory B cells from COVID-19-naïve PAD patients displayed reduced IgG1 class-
280 switching following the primary vaccination series. These cells also displayed impaired CD11c
281 expression, with a positive correlation seen between the percentage of spike-specific CD11c⁺ and
282 IgG1⁺ cells following vaccination. CD11c expression is regulated by BCR stimulation, with CD11c⁺
283 B cells displaying increased expression of genes involved in B cell activation and antigen
284 presentation (38). This suggests that the defect in IgG1 class-switching in some PAD patients
285 may be due to impaired BCR signaling and/or reduced T cell help. IgG1 class switching is rescued

286 in PAD patients following booster vaccination. mRNA booster vaccination also led to an increase
287 in Omicron-specific B cells. Together, these data indicate that administration of mRNA booster
288 vaccination doses may have durable benefits in addition to the short-term increase in total SARS-
289 CoV-2-specific B cells and antibody titers. Many PAD patients in this cohort who historically had
290 poor immune responses to bacterial and other protein antigens (e.g., *Streptococcus*
291 *pneumoniae* polysaccharides, tetanus toxoid, and diphtheria toxin) as part of their initial immune
292 workup responded to mRNA vaccines (**Table S4**). The basis of this difference remains unclear,
293 although it could be due to the unique adjuvant properties of the lipid nanoparticles or in vitro-
294 synthesized mRNA (44).

295
296 Our data also suggest that administration of additional booster vaccines may not lead to an
297 additional short-term increase in SARS-CoV-2-specific B cells. COVID-19 experienced individuals
298 with PAD syndrome had a robust response to the primary vaccination series but displayed no
299 further increase in SARS-CoV-2-specific B cells after administration of a booster vaccine. These
300 individuals also did not display any further increase in their percentage of IgG1⁺ memory B cells
301 or in the antibody avidity (24). This finding is consistent with other studies showing that COVID-
302 19-experienced healthy donors do not display a further increase in their SARS-CoV-2-specific
303 memory B cell response following boosting (45). This does not indicate that additional booster
304 vaccines may not promote additional evolution of the memory B cell repertoire in individuals with
305 PAD syndromes that is independent of cell number (46).

306
307 While the B cell response after completion of the primary vaccination series was assessed in
308 other work, these studies did not detect a SARS-CoV-2-specific memory B cell response above
309 baseline and concluded that vaccination of individuals with PAD syndromes primarily results in a
310 double negative memory B cell response (47, 48). We find that SARS-CoV-2 vaccination induces
311 both a conventional and double negative memory B cell response in most PAD patients that is
312 comparable to healthy donors, and that this response is maintained for at least 150 days after
313 completion of the primary vaccination series. The disparity in results between these studies may
314 be due to a difference in sensitivity in the probes used, as the previous study detected very few
315 cells that bound to spike probes even in healthy donors. Heterogeneity existing within individuals
316 classified as having PAD syndromes may also contribute to difference seen between these
317 studies.

318
319 T cells also have an important role in mediating protective immunity against SARS-CoV-2 (44).

320 Assessment of the SARS-CoV-2-specific T cell response typically involves stimulation of PBMCs
321 with peptides spanning the SARS-CoV-2 spike protein and assaying for activation induced
322 markers (AIM) or intracellular cytokines. Previous studies reported a reduced percentage of
323 interferon gamma-producing T cells following *ex vivo* stimulation in some vaccinated individuals
324 with PAD syndromes (15, 23, 48). We stained PBMCs with tetramers against both S₁₆₇₋₁₈₀ and
325 S₈₁₆₋₈₃₀ tetramers, which bind to immunodominant peptides restricted by the HLA-DPB1*04:01
326 allele. This allowed us to directly detect SARS-CoV-2 specific CD4⁺ T cells without requiring
327 additional stimulation. The SARS-CoV-2-specific CD4⁺ T cell response was comparable in
328 magnitude and phenotype to between COVID-naïve PAD patients and healthy donors that
329 generated a detectable response. Booster vaccination led to a marked increase in the SARS-
330 CoV-2-specific CD4⁺ T cell response. These results suggest that the SARS-CoV-2-specific CD4⁺
331 T cells may contribute to the immune response upon re-infection. However, they do not exclude
332 the possibility that SARS-CoV-2-specific CD4⁺ T cells in some individuals with PAD syndromes
333 may exhibit impaired cytokine production. Further work is needed to assess the magnitude and
334 phenotype of the SARS-CoV-2-specific CD8⁺ T cell response in PAD patients.

335
336 Individuals that are moderately to severely immunocompromised have an elevated risk of severe
337 COVID-19 illness and death and are recommended to receive a third dose of mRNA-based
338 vaccine as part of their primary series. This recommendation is supported by findings from our
339 group and others that immunocompromised individuals have a reduced SARS-CoV-2-specific
340 antibody titer following the initial two-dose vaccination series relative to healthy controls (15, 23,
341 24, 47, 48). Booster vaccination increased the SARS-CoV-2 specific antibody titer and led to the
342 development of Omicron-specific neutralizing antibodies (24). However, the increase in
343 neutralizing antibodies titers displayed following booster vaccination was short-lived and returned
344 to the pre-boost baseline within 90 days (24). Our finding show that a booster dose increases the
345 level and enriches the repertoire of spike-specific memory B cells in PAD patients and might have
346 a long-term benefit beyond the short-lived increase in anti-spike and anti-RBD antibody titers.

347
348 Most individuals with PAD syndromes receive immunoglobulin replacement therapy.
349 Immunoglobulin replacement products administered between May 2021- January 2022 had low
350 levels of SARS-CoV-2-specific antibody titers with low neutralization activity against ancestral
351 strains (24). While the titer of anti-spike and anti-RBD in immunoglobulin replacement products
352 increased over time, the long lag of 9-12 months between collection and production of IVIG and
353 SCIG commercial products may make most available commercial immunoglobulin replacement

354 products less effective against current circulating Omicron variants (33). Although many
355 individuals with PAD might be eligible for long-acting combination monoclonal antibody
356 prophylaxis (e.g., Evusheld [AZD7442]) against COVID-19, recent studies showed substantial
357 (~176-fold) losses in potency against some lineages of Omicron virus (e.g., BA.1.1) (49).
358 Therefore, immunization of individuals with PAD syndromes with mRNA vaccines that include a
359 booster may be the most effective way to induce a protective immune response against SARS-
360 CoV-2 and its variants.

361 **Limitations to the study.** One limitation is that not all patients elected to receive a booster
362 vaccination resulting in lower number of samples in the post-booster time points. This lack of
363 samples is particularly apparent in the COVID-experienced group, which included only three
364 individuals that received a booster vaccination, limiting the conclusions that can be drawn from
365 this data. Another limitation is that the design of this study precluded the collection of a pre-
366 vaccination blood draw from all individuals. Finally, it is important to note that PAD syndromes are
367 a heterogeneous group of diseases with our cohort including individuals with CVID,
368 hypogammaglobulinemia, and specific antibody deficiency. While we did not observe a clear
369 difference in the immune response between these subgroups, there could be heterogeneity
370 between different PAD subgroups that necessitate different vaccination and boosting approaches.

371

372 **MATERIALS AND METHODS**

373 **Primary antibody deficiency syndromes cohort.** The study was approved by the Institutional
374 Review Board of Washington University School of Medicine (Approval # 202104138). Patients
375 were identified by a medical record search for PAD syndromes, and their records were reviewed
376 to confirm their diagnosis and verify they met the inclusion criteria. COVID-19 vaccination status
377 was reviewed, and subjects were contacted if they were within the vaccination window or not yet
378 immunized. Inclusion criteria included males and females over 18 years of age, health care
379 provider-documented PAD syndromes including common variable immunodeficiency (CVID),
380 specific-antibody deficiency, or hypogammaglobulinemia, and the ability to give informed
381 consent. Entry criteria also included receipt of a SARS-CoV-2 vaccine within 14 days of
382 enrollment, receipt of the second dose of mRNA vaccine (Moderna mRNA-1273 or Pfizer
383 BioNTech BNT162b2) within 28 days of the first visit, or receipt of one dose of adenoviral-vector
384 vaccine (J&J Ad26.COVS) within 35 days of initial visit. Exclusion criteria included
385 participation in an investigational study of SARS-CoV-2 vaccines within the past year, history of
386 HIV infection, an active cancer diagnosis, treatment with immunosuppressive medications,

387 history of hematologic malignancy, history of anti-CD20 monoclonal antibody therapy, receipt of
388 live-attenuated vaccine within 30 days or any inactivated vaccine within 14 days of SARS-CoV-2
389 vaccination, blood or blood product donation within 30 days prior to study vaccination, and
390 planned blood donation at any time during or 30 days after the duration of subject study
391 participation.

392
393 In total, 469 charts were reviewed, and 160 subjects were contacted. A total of 30 adults (27
394 females, 3 males) with PAD syndromes met eligibility requirements and agreed to enroll in the
395 study (see Table S1); we note a sex-bias in the enrollees from our PAD cohort, which is not
396 typical for the disease itself. Ages ranged from 20 to 82, with an average age of 48.4 years old.
397 Twenty PAD patients had CVID, six had specific antibody deficiency, and four had
398 hypogammaglobulinemia. Twenty-seven of these subjects had received immunoglobulin
399 replacement therapy before and during the study period from nine different products. Nineteen
400 subjects received the BNT162b2, eight received mRNA-1273, and three received Ad26.COV2.S
401 vaccines. Of the 30 subjects, nine were diagnosed with a prior SARS-CoV-2 infection with a
402 positive nasal swab RT-PCR test, and one received treatment with an anti-SARS-CoV-2
403 monoclonal antibody (bamlanivimab) 90 days prior to study enrollment (**Table S1**).

404
405 All subjects had one mandatory post-vaccine blood sample collection with optional pre-vaccine
406 and follow-up visits at days 60, 90, and 150 (± 14 days) after vaccination. The optional pre-
407 vaccination blood sample was collected up to 14 days before receiving vaccine. For subjects
408 who received a two-dose series of mRNA vaccines, the first post-vaccination blood collection
409 occurred 7 to 28 days after the second dose. For subjects receiving the Ad26.COV2.S single-
410 dose vaccine, the first post-vaccination blood sample was collected 21 to 35 days after
411 immunization. Since the study was non-interventional, patients were informed if they mounted
412 an immune response to the vaccine, but the decision to receive a booster was made between
413 the patient and their physician. Subjects who opted for boosting provided a blood sample up to
414 14 days prior to receiving the booster dose, unless the subject previously provided a sample
415 within 2 weeks as part of the optional post-vaccine assessments. Subjects returned for an
416 additional sample 7 to 28 days after receiving the booster (range 7-27 days, median 17 days,
417 mean 17 days. One patient had her post-booster sample drawn at day 35), with a second and
418 third post-booster visit and sample collection occurring at 90 ± 14 days and 150 ± 14 days.

419

420 **Healthy donor cohort.** Immunocompetent healthy donor volunteer blood samples were
421 obtained as previously described (50). The healthy donor study was approved by the
422 Institutional Review Board of Washington University School of Medicine (Approval #
423 202012081).

424
425 **Quantification and statistical analysis.** Statistical significance was determined using Prism
426 Version 9 (GraphPad). Statistical analysis was determined by one-way ANOVA, unpaired t-test,
427 mixed model analysis, or two-way ANOVA with Fisher's least significant difference testing.
428 Associations were calculated using Pearson rank correlation and are shown with Pearson trend
429 lines for visualization.

430
431 **ACKNOWLEDGEMENTS:**
432 This study was supported by grants and contracts from NIH: DP2AI169978 and K22AI153015 [all
433 to B.J.L.], R01 AI157155, U01 AI151810, and 75N93019C00051 [all to M.S.D.], U01AI141990,
434 U01AI150747, HHSN272201400006C, HHSN272201400008C, and 75N93019C00051 [all to
435 A.H.E.], and R01 DK084242 [to P.L.K.]. The study also was supported by a VA Merit Award
436 BX002882 [to P.L.K.]. This study utilized samples obtained from the Washington University School
437 of Medicine COVID-19 biorepository, which is supported by the NIH/National Center for
438 Advancing Translational Sciences (UL1 TR002345). The WU368 studies were reviewed and
439 approved by the Washington University Institutional Review Board (approval no. 308 202012081).
440 The authors thank Likui Yang and the Bursky Center for Human Immunology Tetramer Core for
441 their help generating tetramer reagents. The authors also express their gratitude to all study
442 participants.

443
444 **AUTHOR CONTRIBUTIONS:**
445 F.J.L. performed experiments, analyzed the data, and prepared the manuscript.
446 A.L.T.D. enrolled subjects, collected demographic and clinical data, processed PBMC samples,
447 performed experiments, and analyzed data.
448 H.G.D.A., F.R.Z. and E.R. processed PBMC samples.
449 L.J.A. and D.H.F. generated crucial reagents.
450 C.H.H. performed experiments and analyzed the data.
451 C.L., L.A.V, and R.E.C designed and performed antibody neutralization experiments and
452 analyzed data.

453 J.M.M and C.J.R collected demographic and clinical data, enrolled patients, and provided patient
454 care.

455 H.J.W., And.K, T.B.D, Ant.K. and Z.R. provided patient care.

456 T.L.M. wrote the study protocol, managed IRB compliance, enrolled patients, and processed
457 patient samples.

458 C.C.O collected patient demographic and clinical data, enrolled patients, and processed samples.

459 S.R. planned experiments and analyzed data.

460 A.H.E and J.T contributed samples from the healthy donor cohort.

461 J.A.O and R.M.P wrote and maintained the Institutional Review Board protocol, recruited, and
462 phlebotomized participants and coordinated sample collection of healthy donors.

463 P.L.K. supervised the project.

464 P.A.M. generated crucial reagents.

465 M.S.D planned experiments and analyzed data.

466 O.Z. designed the study, wrote the study protocol, processed PBMC samples, performed
467 experiments, analyzed the data, and supervised the project.

468 B.J.L. planned the experiments, analyzed the data, prepared the manuscript, and supervised the
469 project.

470

471 **COMPETING INTERESTS:**

472 M.S.D. is a consultant for Inbios, Vir Biotechnology, Senda Biosciences, and Carnival
473 Corporation, and is on the Scientific Advisory Boards of Moderna and Immunome. The Diamond
474 laboratory has received unrelated funding support in sponsored research agreements from
475 Moderna, Vir Biotechnology, Immunome, and Emergent BioSolutions.

476 O.Z. and family own Moderna stock. The Ellebedy laboratory received unrelated funding support
477 from Emergent BioSolutions and AbbVie.

478 A.H.E. is a consultant for Mubadala Investment Company and the founder of ImmuneBio
479 Consulting. J.S.T. is a consultant for Gerson Lehrman Group.

480 J.S.T. and A.H.E. are recipients of a licensing agreement with Abbvie that is unrelated to this
481 manuscript.

482

483 **DATA AVAILABILITY:**

484 All data reported in this paper will be shared upon request. Any additional information required to
485 reanalyze the data reported in this paper is available from the corresponding authors upon
486 request.




Figure 1

487 **Figure 1. COVID-19-experienced PAD patients display elevated spike-specific B cell**
488 **response following primary vaccination series.** (a) Schematic of study design including time
489 points in which PBMCs were obtained and number of samples per time point for each group. (b)
490 Representative FACS plots of the gating strategy used to identify activated (IgD^{lo}) Spike⁺ B
491 cells. (c) Percentage of activated Spike⁺ cells amongst the B (Live CD19⁺ CD3⁻) cell population
492 in the healthy donor (left, white), COVID-19-naïve PAD (middle left, red), and COVID-19-
493 experienced PAD (middle right, green) cohorts. Aggregate of mean percentage of B cells that
494 are Spike⁺ activated cells in all groups is shown on right. (d) Percentage of memory (IgD^{lo}
495 CD20⁺ CD38^{int-lo} CD27⁺) Spike⁺ cells amongst the B cell population in the healthy donor (left,
496 white), COVID-19-naïve PAD (middle, red), and COVID-19-experienced PAD (middle, green)
497 cohorts. Aggregate of mean percentage of B cells that are Spike⁺ memory cells in all groups is
498 shown on right. (e) Percentage of double negative (IgD^{lo} CD20⁺ CD38^{int-lo} CD27⁻) Spike⁺ cells
499 amongst the B cell population in the healthy donor (left, white), COVID-19-naïve PAD (middle,
500 red), and COVID-19-experienced PAD (middle, green) cohorts. Aggregate of mean percentage
501 of B cells that are double negative Spike⁺ cells in all groups is shown on right. (f) Percentage of
502 non-class-switched (IgD⁺ CD20⁺ CD38^{int-lo} CD27⁺) Spike⁺ cells amongst the B cell population in
503 the healthy donor (left, white), COVID-19-naïve PAD (middle, red), and COVID-19-experienced
504 PAD (middle, green) cohorts. Aggregate of mean percentage of B cells that are Spike⁺ non-
505 class-switched cells in all groups is shown on right. Statistical analyses in c-f were performed
506 using a mixed-effects model (for trends found between time points) or two-way ANOVA (for
507 trends found between groups in the aggregate graphs) with Fisher's least significant difference
508 testing. Significance testing between time points was limited to comparisons relative to T1. On
509 the aggregate graphs, error bars were displayed based on the standard error of the mean.
510 Above the aggregate graphs, an orange asterisk indicates a comparison between the COVID-
511 19-naïve and COVID-19-experienced groups, and a purple asterisk indicates a comparison
512 between the COVID-19-experienced and healthy donor groups (*, $p < 0.05$; **, $p < 0.01$; ***,
513 $p < 0.001$; ****, $p < 0.001$). See also Figure S2.




Figure 2

514 **Figure 2. COVID-19-naïve PAD patients display elevated spike-specific B cell response**
515 **following booster vaccination. (a)** Percentage of activated Spike⁺ cells amongst the B (Live
516 CD19⁺ CD3⁺) cell population in the healthy donor (left, white), COVID-19-naïve PAD (middle left,
517 red), and COVID-19-experienced PAD (middle right, green) cohorts. Aggregate of mean
518 percentage of B cells that are Spike⁺ activated cells in all groups is shown on right. **(b)**
519 Percentage of memory (IgD^{lo} CD20⁺ CD38^{int-lo} CD27⁺) Spike⁺ cells amongst the B cell population
520 in the healthy donor (left, white), COVID-19-naïve PAD (middle, red), and COVID-19-
521 experienced PAD (middle, green) cohorts. Aggregate of mean percentage of B cells that are
522 Spike⁺ memory cells in all groups is shown on right. **(c)** Percentage of double negative (IgD^{lo}
523 CD20⁺ CD38^{int-lo} CD27⁻) Spike⁺ cells amongst the B cell population in the healthy donor (left,
524 white), COVID-19-naïve PAD (middle, red), and COVID-19-experienced PAD (middle, green)
525 cohorts. Aggregate of mean percentage of B cells that are double negative Spike⁺ cells in all
526 groups is shown on right. **(d)** Percentage of non-class-switched (IgD⁺ CD20⁺ CD38^{int-lo} CD27⁺)
527 Spike⁺ cells amongst the B cell population in the healthy donor (left, white), COVID-19-naïve
528 PAD (middle, red), and COVID-19-experienced PAD (middle, green) cohorts. Aggregate of
529 mean percentage of B cells that are Spike⁺ non-class-switched cells in all groups is shown on
530 right. **(e)** Correlation between percentage of B cells that are Spike⁺ (left) or RBD⁺ (right) memory
531 cells prior to administration of booster vaccination and the serum neutralizing activity against
532 WA1/2020 at B1. **(f)** Correlation between percentage of B cells that are Spike⁺ (left) or RBD⁺
533 (right) memory cells prior to administration of booster vaccination and the serum neutralizing
534 activity against B.1.617.2 at B1. **(g)** Correlation between percentage of B cells that are Spike⁺
535 (left) or RBD⁺ (right) memory cells prior to administration of booster vaccination and the serum
536 neutralizing activity against B.1.1.529 at B1. The pre-boost group consists of the last sample
537 obtained from each patient prior to booster vaccination. Statistical analyses were performed
538 using a mixed effects model (for trends found between time points) with Fisher's least significant
539 difference testing in a-d, or a Pearson rank correlation (with Pearson trend lines for
540 visualization) in e-g. (*, $p < 0.05$; **, $p < 0.01$). Significance testing between time points was
541 limited to comparisons relative to pre-boost. On the aggregate graphs, error bars were
542 calculated based on the standard error of the mean. See also Figure S3.




Figure 3

543 **Figure 3. Spike-specific memory B cells from COVID-19-naïve PAD patients display**
544 **reduced IgG1 class switching following primary vaccination series.** (a) Representative
545 FACS plots of the gating strategy used to identify the isotype of Spike⁺ memory (IgD^{lo} CD20⁺
546 CD38^{int-lo} CD27⁺) B cells. (b) Percentage of Spike⁺ memory B cells that are IgG1⁺ in the healthy
547 donor (left, white), COVID-19-naïve PAD (middle left, red), and COVID-19-experienced PAD
548 (middle right, green) cohorts. Aggregate of mean percentage of IgG1⁺ cells in all groups is
549 shown on right. (c) Percentage of Spike⁺ memory B cells that are IgM⁺ in the healthy donor (left,
550 white), COVID-19-naïve PAD (middle left, red), and COVID-19-experienced PAD (middle right,
551 green) cohorts. Aggregate of mean percentage of IgM⁺ cells in all groups is shown on right. (d)
552 Percentage of Spike⁺ memory B cells that are IgA⁺ in the healthy donor (left, white), COVID-19-
553 naïve PAD (middle left, red), and COVID-19-experienced PAD (middle right, green) cohorts.
554 Aggregate of mean percentage of IgA⁺ cells in all groups is shown on right. (e) Percentage of
555 Spike⁺ memory B cells that are IgG2⁺ in the healthy donor (left, white), COVID-19-naïve PAD
556 (middle left, red), and COVID-19-experienced PAD (middle right, green) cohorts. Aggregate of
557 mean percentage of IgG2⁺ cells in all groups is shown on right. (f) Percentage of Spike⁺ memory
558 B cells that are IgG3⁺ in the healthy donor (left, white), COVID-19-naïve PAD (middle left, red),
559 and COVID-19-experienced PAD (middle right, green) cohorts. Aggregate of mean percentage
560 of IgG3⁺ cells in all groups is shown on right. Statistical analyses in b-d were performed using a
561 mixed effects model (for trends found between time points) or two-way ANOVA (for trends found
562 between groups in the aggregate graphs) with Fisher's least significant difference testing.
563 Significance testing between time points was limited to comparisons relative to T1. On the
564 aggregate graphs, error bars were calculated based on the standard error of the mean. Above
565 the aggregate graphs, a green asterisk indicates a comparison between the COVID-19-naïve
566 and healthy donor groups, an orange asterisk indicates a comparison between the COVID-19-
567 naïve and COVID-19-experienced groups, and a purple asterisk indicates a comparison
568 between the COVID-19-experienced and healthy donor groups (*, $p < 0.05$; **, $p < 0.01$; ***, $p <$
569 0.001). See also Figure S4.
570




Figure 4

571 **Figure 4. Spike-specific memory B cells from PAD patients display reduced CD11c**
572 **expression class.** (a) Representative FACS plots of the expression of CD11c and CXCR5 on
573 Spike⁺ memory (IgD^{lo} CD20⁺ CD38^{int-lo} CD27⁺) B cells. (b) Representative FACS plots of the
574 expression of CD11c and CXCR5 on Spike⁺ double negative (IgD^{lo} CD20⁺ CD38^{int-lo} CD27⁻) B
575 cells. (c) Percentage of Spike⁺ memory B cells that are CD11c⁺ in the healthy donor (left,
576 white), COVID-19-naïve PAD (middle left, red), and COVID-19-experienced PAD (middle right,
577 green) cohorts. Aggregate of mean percentage of CD11c⁺ cells in all groups is shown on right.
578 (d) Correlation between percentage of Spike⁺ memory B cells that are IgG1⁺ and CD11c⁺ at T1
579 (left) or B1 (right). Associations for d are calculated using Pearson rank correlation and are
580 shown with Pearson trend lines for visualization. (e) Percentage Spike⁺ memory B cells that are
581 CXCR5⁺ in the healthy donor (left, white), COVID-19-naïve PAD (middle left, red), and COVID-
582 19-experienced PAD (middle right, green) cohorts. Aggregate of mean percentage of CXCR5⁺
583 cells in all groups is shown on right. (f) Percentage of Spike⁺ double negative B cells that are
584 CD11c⁺ CXCR5⁻ in the healthy donor (left, white), COVID-19-naïve PAD (middle left, red), and
585 COVID-19-experienced PAD (middle right, green) cohorts. Aggregate of mean percentage of
586 are CD11c⁺ CXCR5⁻ cells in all groups is shown on right. (g) Percentage of Spike⁺ double
587 negative B cells that are CD11c⁻ CXCR5⁺ in the healthy donor (left, white, COVID-19-naïve PAD
588 (middle left, red), and COVID-19-experienced PAD (middle right, green) cohorts. Aggregate of
589 mean percentage of are CD11c⁻ CXCR5⁺ cells in all groups is shown on right. Statistical
590 analyses in c, e-g were performed using a mixed effects model (for trends found between time
591 points) or two-way ANOVA (for trends found between groups in the aggregate graphs) with
592 Fisher's least significant difference testing. Significance testing between time points was limited
593 to comparisons relative to T1. On the aggregate graphs, error bars were calculated based on
594 the standard error of the mean. Above the aggregate graphs, a green asterisk indicates a
595 comparison between the COVID-19-naïve and healthy donor groups, an orange asterisk
596 indicates a comparison between the COVID-19-naïve and COVID-19-experienced groups, and
597 a purple asterisk indicates a comparison between the COVID-19-experienced and healthy donor
598 groups (*, $p < 0.05$; **, $p < 0.01$; ***, $p < 0.001$; ****, $p < 0.0001$). See also Figure S5.




Figure 5

599 **Figure 5. PAD patients display unimpaired SARS-CoV-2-specific CD4⁺ T cell response**
600 **following vaccination.** (a) Representative FACS plots of the gating strategy used to identify
601 S₁₆₇₋₁₈₀⁺ and S₈₁₆₋₈₃₀⁺ CD4⁺ T cells. (b) Percentage of CD4⁺ (Live CD3⁺ CD19⁻ CD4⁺ CD8⁻) T
602 cells that are S₁₆₇₋₁₈₀⁺ in the healthy donor (left, white), COVID-19-naïve PAD (middle left, red),
603 and COVID-19-experienced PAD (middle right, green) cohorts. Aggregate of mean percentage
604 of S₁₆₇₋₁₈₀⁺ cells in all groups is shown on right. (c) Percentage of CD4⁺ T cells that are S₈₁₆₋₈₃₀⁺
605 in the healthy donor (left, white), COVID-19-naïve PAD (middle left, red), and COVID-19-
606 experienced PAD (middle right, green) cohorts. Aggregate of mean percentage of S₈₁₆₋₈₃₀⁺ cells
607 in all groups is shown on right. (d) Combined percentage of CD4⁺ T cells that are tetramer⁺
608 (S₁₆₇₋₁₈₀⁺ or S₈₁₆₋₈₃₀⁺) in the healthy donor (left, white), COVID-19-naïve PAD (middle left, red),
609 and COVID-19-experienced PAD (middle right, green) cohorts. Aggregate of mean percentage
610 of tetramer⁺ cells in all groups is shown on right. (e) Correlation between percentage of B cells
611 that are Spike⁺ (left) or RBD⁺ (right) memory (IgD^{lo} CD20⁺ CD38^{int-lo} CD27⁺) cells and the
612 percentage of CD4⁺ T cells that are Tetramer⁺ at T1. (f) Correlation between percentage of B
613 cells that are Spike⁺ (left) or RBD⁺ (right) memory cells and the percentage of CD4⁺ T cells that
614 are Tetramer⁺ at B1. Associations for e and f are calculated using Pearson rank correlation and
615 are shown with Pearson trend lines for visualization. Statistical analyses in b-d were performed
616 using a mixed effects model (for trends found between time points) or two-way ANOVA (for
617 trends found between groups in the aggregate graphs) with Fisher's least significant difference
618 testing. Significance testing between time points was limited to comparisons relative to T1. On
619 the aggregate graphs, error bars were calculated based on the standard error of the mean.
620 Above the aggregate graphs, an orange asterisk indicates a comparison between the COVID-
621 19-naïve and COVID-19-experienced groups, and a purple asterisk indicates a comparison
622 between the COVID-19-experienced and healthy donor groups (*, $p < 0.05$; **, $p < 0.01$).




Figure 6

623 **Figure 6. Phenotype of SARS-CoV-2-specific CD4⁺ T cell response following vaccination**
624 **in PAD patients.** (a) Representative FACS plots of the expression of PD1, ICOS, CD38, HLA-
625 DR, and CD45RO on Tetramer⁺ CD4⁺ (Live CD3⁺ CD19⁻ CD4⁺ CD8⁻ S₁₆₇₋₁₈₀⁺ or S₈₁₆₋₈₃₀⁺) T cells.
626 (b) Representative FACS plots of the expression of CD27 and CCR7 on CD45RO⁺ Tetramer⁺
627 CD4⁺ T cells. (c) Percentage of Tetramer⁺ CD4⁺ T cells that are PD1⁺ in the healthy donor (left,
628 white), COVID-19-naïve PAD (middle, red), and COVID-19-experienced PAD (middle, green)
629 cohorts. Aggregate of mean percentage of Tetramer⁺ T cells that are PD1⁺ in all groups is
630 shown on right. (d) Percentage of Tetramer⁺ CD4⁺ T cells that are ICOS⁺ in the healthy donor
631 (left, white), COVID-19-naïve PAD (middle, red), and COVID-19-experienced PAD (middle,
632 green) cohorts. Aggregate of mean percentage of Tetramer⁺ T cells that are ICOS⁺ in all groups
633 is shown on right. (e) Percentage of Tetramer⁺ CD4⁺ T cells that are CD38⁺ in the healthy donor
634 (left, white), COVID-19-naïve PAD (middle, red), and COVID-19-experienced PAD (middle,
635 green) cohorts. Aggregate of mean percentage of Tetramer⁺ T cells that are CD38⁺ in all groups
636 is shown on right. (f) Percentage of Tetramer⁺ CD4⁺ T cells that are HLA-DR⁺ in the healthy
637 donor (left, white), COVID-19-naïve PAD (middle, red), and COVID-19-experienced PAD
638 (middle, green) cohorts. Aggregate of mean percentage of Tetramer⁺ T cells that are HLA-DR⁺
639 in all groups is shown on right. (g) Percentage of Tetramer⁺ T cells that are central memory
640 (CD45RO⁺ CD27⁺ CCR7⁺) cells in the healthy donor (left, white), COVID-19-naïve PAD (middle,
641 red), and COVID-19-experienced PAD (middle, green) cohorts. Aggregate of mean percentage
642 of Tetramer⁺ T cells that are central memory cells in all groups is shown on right. (h) Percentage
643 of Tetramer⁺ T cells that are effector memory (CD45RO⁺ CD27⁺ CCR7⁻) cells in the healthy
644 donor (left, white), COVID-19-naïve PAD (middle, red), and COVID-19-experienced PAD
645 (middle, green) cohorts. Aggregate of mean percentage of Tetramer⁺ T cells that are effector
646 memory in all groups is shown on right. On the aggregate graphs, error bars were calculated
647 based on the standard error of the mean.




Figure 7

648 **Figure 7. PAD patients display elevated Omicron-specific B cell response following**
649 **booster vaccination.** (a) Representative FACS plots of the percentage of Omicron-specific B
650 cells among the memory (IgD^{lo} CD20⁺ CD38^{int-lo} CD27⁺) B cell population prior to and post
651 booster vaccination in COVID-19-naïve (left) and COVID-19-experienced (right) individuals with
652 PAD syndromes. (b) Percentage of activated Omicron⁺ cells amongst the B (Live CD19⁺ CD3⁻)
653 cell population in the healthy donor (left, white), COVID-19-naïve PAD (middle left, red), and
654 COVID-19-experienced PAD (middle right, green) cohorts. Aggregate of mean percentage of B
655 cells that are Omicron⁺ activated cells in all groups is shown on right. (c) Percentage of memory
656 Omicron⁺ cells amongst the B cell population in the healthy donor (left, white), COVID-19-naïve
657 PAD (middle, red), and COVID-19-experienced PAD (middle, green) cohorts. Aggregate of
658 mean percentage of B cells that are Omicron⁺ memory cells in all groups is shown on right. (d)
659 Percentage of double negative Omicron⁺ cells amongst the B cell population in the healthy
660 donor (left, white), COVID-19-naïve PAD (middle, red), and COVID-19-experienced PAD
661 (middle, green) cohorts. Aggregate of mean percentage of B cells that are double negative
662 Omicron⁺ cells in all groups is shown on right. (e) Percentage of non-class-switched (IgD⁺
663 CD20⁺ CD38^{int-lo} CD27⁺) Omicron⁺ cells amongst the B cell population in the healthy donor (left,
664 white), COVID-19-naïve PAD (middle, red), and COVID-19-experienced PAD (middle, green)
665 cohorts. Aggregate of mean percentage of B cells that are Omicron⁺ non-class-switched cells in
666 all groups is shown on right. Statistical analyses in b-e were performed using a mixed effects
667 model (for trends found between time points) or two-way ANOVA (for trends found between
668 groups in the aggregate graphs) with Fisher's least significant difference testing. Significance
669 testing between time points was limited to comparisons relative to pre-boost. On the aggregate
670 graphs, error bars were calculated based on the standard error of the mean. Above the
671 aggregate graphs, an orange asterisk indicates a comparison between the COVID-19-naïve and
672 COVID-19-experienced groups (*, $p < 0.05$; **, $p < 0.01$).

673 **REFERENCES**

674

- 675 1. L. R. Baden, H. M. E. Sahly, B. Essink, K. Kotloff, S. Frey, R. Novak, D. Diemert, S. A.
676 Spector, N. Rouphael, C. B. Creech, J. McGettigan, S. Khetan, N. Segall, J. Solis, A. Brosz, C.
677 Fierro, H. Schwartz, K. Neuzil, L. Corey, P. Gilbert, H. Janes, D. Follmann, M. Marovich, J.
678 Mascola, L. Polakowski, J. Ledgerwood, B. S. Graham, H. Bennett, R. Pajon, C. Knightly, B.
679 Leav, W. Deng, H. Zhou, S. Han, M. Ivarsson, J. Miller, T. Zaks, C. S. Group, Efficacy and
680 Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *New Engl J Med*. 384, 403–416 (2020).
- 681 2. F. P. Polack, S. J. Thomas, N. Kitchin, J. Absalon, A. Gurtman, S. Lockhart, J. L. Perez, G. P.
682 Marc, E. D. Moreira, C. Zerbini, R. Bailey, K. A. Swanson, S. Roychoudhury, K. Koury, P. Li, W.
683 V. Kalina, D. Cooper, R. W. Frenck, L. L. Hammitt, Ö. Türeci, H. Nell, A. Schaefer, S. Ünal, D.
684 B. Tresnan, S. Mather, P. R. Dormitzer, U. Şahin, K. U. Jansen, W. C. Gruber, C. C. T. Group,
685 Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *New Engl J Med*. 383, 2603–
686 2615 (2020).
- 687 3. L. Tang, D. R. Hijano, A. H. Gaur, T. L. Geiger, E. J. Neufeld, J. M. Hoffman, R. T. Hayden,
688 Asymptomatic and Symptomatic SARS-CoV-2 Infections After BNT162b2 Vaccination in a
689 Routinely Screened Workforce. *Jama*. 325 (2021), doi:10.1001/jama.2021.6564.
- 690 4. Y. Angel, A. Spitzer, O. Henig, E. Saiag, E. Sprecher, H. Padova, R. Ben-Ami, Association
691 Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-
692 CoV-2 Infections Among Health Care Workers. *Jama*. 325 (2021), doi:10.1001/jama.2021.7152.
- 693 5. E. J. Haas, F. J. Angulo, J. M. McLaughlin, E. Anis, S. R. Singer, F. Khan, N. Brooks, M.
694 Smaja, G. Mircus, K. Pan, J. Southern, D. L. Swerdlow, L. Jodar, Y. Levy, S. Alroy-Preis, Impact
695 and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19
696 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an
697 observational study using national surveillance data. *Lancet*. 397, 1819–1829 (2021).
- 698 6. G. Regev-Yochay, S. Amit, M. Bergwerk, M. Lipsitch, E. Leshem, R. Kahn, Y. Lustig, C.
699 Cohen, R. Doolman, A. Ziv, I. Novikov, C. Rubin, I. Gimpelevich, A. Huppert, G. Rahav, A. Afek,
700 Y. Kreiss, Decreased infectivity following BNT162b2 vaccination: A prospective cohort study in
701 Israel. *Lancet Regional Heal - Europe*. 7, 100150 (2021).
- 702 7. J. Sadoff, G. Gray, A. Vandebosch, V. Cárdenas, G. Shukarev, B. Grinsztejn, P. A. Goepfert,
703 C. Truyers, H. Fennema, B. Spiessens, K. Offergeld, G. Scheper, K. L. Taylor, M. L. Robb, J.
704 Treanor, D. H. Barouch, J. Stoddard, M. F. Ryser, M. A. Marovich, K. M. Neuzil, L. Corey, N.
705 Cauwenberghs, T. Tanner, K. Hardt, J. Ruiz-Guiñazú, M. L. Gars, H. Schuitemaker, J. V. Hoof,
706 F. Struyf, M. Douoguih, E. S. Group, Safety and Efficacy of Single-Dose Ad26.COVS.2.S Vaccine
707 against Covid-19. *New Engl J Medicine*. 384, NEJMoa2101544 (2021).
- 708 8. W. Kim, J. Q. Zhou, S. C. Horvath, A. J. Schmitz, A. J. Sturtz, T. Lei, Z. Liu, E. Kalaidina, M.
709 Thapa, W. B. Alsoussi, A. Haile, M. K. Klebert, T. Suessen, L. Parra-Rodriguez, P. A. Mudd, S.
710 P. J. Whelan, W. D. Middleton, S. A. Teefey, I. Pusic, J. A. O'Halloran, R. M. Presti, J. S.
711 Turner, A. H. Ellebedy, Germinal centre-driven maturation of B cell response to mRNA
712 vaccination. *Nature*. 604, 141–145 (2022).

- 713 9. E. Cameroni, J. E. Bowen, L. E. Rosen, C. Saliba, S. K. Zepeda, K. Culap, D. Pinto, L. A.
714 VanBlargan, A. D. Marco, J. di Iulio, F. Zatta, H. Kaiser, J. Noack, N. Farhat, N. Czudnochowski,
715 C. Havenar-Daughton, K. R. Sprouse, J. R. Dillen, A. E. Powell, A. Chen, C. Maher, L. Yin, D.
716 Sun, L. Soriaga, J. Bassi, C. Silacci-Fregni, C. Gustafsson, N. M. Franko, J. Logue, N. T. Iqbal,
717 I. Mazzitelli, J. Geffner, R. Grifantini, H. Chu, A. Gori, A. Riva, O. Giannini, A. Ceschi, P. Ferrari,
718 P. E. Cippà, A. Franzetti-Pellanda, C. Garzoni, P. J. Halfmann, Y. Kawaoka, C. Hebner, L. A.
719 Purcell, L. Piccoli, M. S. Pizzuto, A. C. Walls, M. S. Diamond, A. Telenti, H. W. Virgin, A.
720 Lanzavecchia, G. Snell, D. Veessler, D. Corti, Broadly neutralizing antibodies overcome SARS-
721 CoV-2 Omicron antigenic shift. *Nature*. 602, 664–670 (2022).
- 722 10. K. Wang, Z. Jia, L. Bao, L. Wang, L. Cao, H. Chi, Y. Hu, Q. Li, Y. Zhou, Y. Jiang, Q. Zhu, Y.
723 Deng, P. Liu, N. Wang, L. Wang, M. Liu, Y. Li, B. Zhu, K. Fan, W. Fu, P. Yang, X. Pei, Z. Cui, L.
724 Qin, P. Ge, J. Wu, S. Liu, Y. Chen, W. Huang, Q. Wang, C.-F. Qin, Y. Wang, C. Qin, X. Wang,
725 Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants. *Nature*.
726 603, 919–925 (2022).
- 727 11. W. F. Garcia-Beltran, K. J. St. Denis, A. Hoelzemer, E. C. Lam, A. D. Nitido, M. L. Sheehan,
728 C. Berrios, O. Ofoman, C. C. Chang, B. M. Hauser, J. Feldman, A. L. Roederer, D. J. Gregory,
729 M. C. Poznansky, A. G. Schmidt, A. J. Iafrate, V. Naranbhai, A. B. Balazs, mRNA-based
730 COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron
731 variant. *Cell*. 185, 457-466.e4 (2022).
- 732 12. A. Muik, A.-K. Wallisch, B. Sängler, K. A. Swanson, J. Mühl, W. Chen, H. Cai, D. Maurus, R.
733 Sarkar, Ö. Türeci, P. R. Dormitzer, U. Şahin, Neutralization of SARS-CoV-2 lineage B.1.1.7
734 pseudovirus by BNT162b2 vaccine-elicited human sera. *Science*. 371, 1152–1153 (2021).
- 735 13. I. Meyts, G. Buccioli, I. Quinti, B. Neven, A. Fischer, E. Seoane, E. Lopez-Granados, C.
736 Gianelli, A. Robles-Marhuenda, P.-Y. Jeandel, C. Paillard, V. G. Sankaran, Y. Y. Demirdag, V.
737 Lougaris, A. Aiuti, A. Plebani, C. Milito, V. ASH. Dalm, K. Guevara-Hoyer, S. Sánchez-Ramón,
738 L. Bezrodnik, F. Barzaghi, L. I. Gonzalez-Granado, G. R. Hayman, G. Uzel, L. O. Mendonça, C.
739 Agostini, G. Spadaro, R. Badolato, A. Soresina, F. Vermeulen, C. Bosteels, B. N. Lambrecht, M.
740 Keller, P. J. Mustillo, R. S. Abraham, S. Gupta, A. Ozen, E. Karakoc-Aydiner, S. Baris, A. F.
741 Freeman, M. Yamazaki-Nakashimada, S. Scheffler-Mendoza, S. Espinosa-Padilla, A. R.
742 Gennery, S. Jolles, Y. Espinosa, M. C. Poli, C. Fieschi, F. Hauck, C. Cunningham-Rundles, N.
743 Mahlaoui, I. C. of I. E. of Immunity, K. Warnatz, K. E. Sullivan, S. G. Tangye, Coronavirus
744 disease 2019 in patients with inborn errors of immunity: An international study. *J Allergy Clin*
745 *Immunol*. 147, 520–531 (2021).
- 746 14. A. M. Shields, A. Anantharachagan, G. Arumugakani, K. Baker, S. Bahal, H. Baxendale, W.
747 Bermingham, M. Bhole, E. Boules, P. Bright, C. Chopra, L. Cliffe, B. Cleave, J. Dempster, L.
748 Devlin, F. Dhalla, L. Diwakar, E. Drewe, C. Duncan, M. Dziadzio, S. Elcombe, S. Elkhalfi, A.
749 Gennery, H. Ghanta, S. Goddard, S. Grigoriadou, S. Hackett, G. Hayman, R. Herriot, A.
750 Herwadkar, A. Huissoon, R. Jain, S. Jolles, S. Johnston, S. Khan, J. Laffan, P. Lane, L.
751 Leeman, D. M. Lowe, S. Mahabir, D. J. M. Lochlainn, E. McDermott, S. Misbah, F. Moghaddas,
752 H. Morsi, S. Murng, S. Noorani, R. O'Brien, S. Patel, A. Price, T. Rahman, S. Seneviratne, A.
753 Shrimpton, C. Stroud, M. Thomas, K. Townsend, P. Vaitla, N. Verma, A. Williams, S. O. Burns,
754 S. Savic, A. G. Richter, Outcomes following SARS-CoV-2 infection in patients with primary and
755 secondary immunodeficiency in the United Kingdom. *Clin Exp Immunol*, uxac008 (2022).

- 756 15. D. Arroyo-Sánchez, O. Cabrera-Marante, R. Laguna-Goya, P. Almendro-Vázquez, O.
757 Carretero, F. J. Gil-Etayo, P. Suárez-Fernández, P. Pérez-Romero, E. R. de Frías, A. Serrano,
758 L. M. Allende, D. Pleguezuelo, E. Paz-Artal, Immunogenicity of Anti-SARS-CoV-2 Vaccines in
759 Common Variable Immunodeficiency. *J Clin Immunol.* 42, 240–252 (2022).
- 760 16. S. A. Apostolidis, M. Kakara, M. M. Painter, R. R. Goel, D. Mathew, K. Lenzi, A. Rezk, K. R.
761 Patterson, D. A. Espinoza, J. C. Kadri, D. M. Markowitz, C. E. Markowitz, I. Mexhitaj, D. Jacobs,
762 A. Babb, M. R. Betts, E. T. L. Prak, D. Weiskopf, A. Grifoni, K. A. Lundgreen, S. Gouma, A.
763 Sette, P. Bates, S. E. Hensley, A. R. Greenplate, E. J. Wherry, R. Li, A. Bar-Or, Cellular and
764 humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple
765 sclerosis on anti-CD20 therapy. *Nat Med.* 27, 1990–2001 (2021).
- 766 17. E. Azzolini, C. Pozzi, L. Germagnoli, B. Oresta, N. Carriglio, M. Calleri, C. Selmi, M. D.
767 Santis, S. Finazzi, C. Carlo-Stella, A. Bertuzzi, F. Motta, A. Ceribelli, A. Mantovani, F. Bonelli,
768 M. Rescigno, mRNA COVID-19 vaccine booster fosters B- and T-cell responses in
769 immunocompromised patients. *Life Sci Alliance.* 5, e202201381 (2022).
- 770 18. N. A. Kennedy, S. Lin, J. R. Goodhand, N. Chanchlani, B. Hamilton, C. Bewshea, R. Nice,
771 D. Chee, J. F. Cummings, A. Fraser, P. M. Irving, N. Kamperidis, K. B. Kok, C. A. Lamb, J.
772 Macdonald, S. Mehta, R. C. Pollok, T. Raine, P. J. Smith, A. M. Verma, S. Jochum, T. J.
773 McDonald, S. Sebastian, C. W. Lees, N. Powell, T. Ahmad, C. to the C. I. study, *Gut*, in press,
774 doi:10.1136/gutjnl-2021-324789.
- 775 19. S. K. Mahil, K. Bechman, A. Raharja, C. Domingo-Vila, D. Baudry, M. A. Brown, A. P. Cope,
776 T. Dasandi, C. Graham, T. Lechmere, M. H. Malim, F. Meynell, E. Pollock, J. Seow, K.
777 Sychowska, J. N. Barker, S. Norton, J. B. Galloway, K. J. Doores, T. I. M. Tree, C. H. Smith,
778 The effect of methotrexate and targeted immunosuppression on humoral and cellular immune
779 responses to the COVID-19 vaccine BNT162b2: a cohort study. *Lancet Rheumatology.* 3,
780 e627–e637 (2021).
- 781 20. T. Bachelet, J.-P. Bourdenx, C. Martinez, S. Mucha, P. Martin-Dupont, V. Perier, A.
782 Pommereau, Humoral response after SARS-CoV-2 mRNA vaccines in dialysis patients:
783 Integrating anti-SARS-CoV-2 Spike-Protein-RBD antibody monitoring to manage dialysis
784 centers in pandemic times. *Plos One.* 16, e0257646 (2021).
- 785 21. C. Danthu, S. Hantz, A. Dahlem, M. Duval, B. Ba, M. Guibbert, Z. E. Ouafi, S. Ponsard, I.
786 Berrahal, J. M. Achard, F. Bocquentin, V. Allot, J. P. Rerolle, S. Alain, F. Toure, *J Am Soc*
787 *Nephrol*, in press, doi:10.1681/asn.2021040490.
- 788 22. P. Deepak, W. Kim, M. A. Paley, M. Yang, A. B. Carvidi, E. G. Demissie, A. A. El-Qunni, A.
789 Haile, K. Huang, B. Kinnett, M. J. Liebeskind, Z. Liu, L. E. McMorrow, D. Paez, N. Pawar, D. C.
790 Perantie, R. E. Schriefer, S. E. Sides, M. Thapa, M. Gergely, S. Abushamma, S. Akuse, M.
791 Klebert, L. Mitchell, D. Nix, J. Graf, K. E. Taylor, S. Chahin, M. A. Ciorba, P. Katz, M.
792 Matloubian, J. A. O'Halloran, R. M. Presti, G. F. Wu, S. P. J. Whelan, W. J. Buchser, L. S.
793 Gensler, M. C. Nakamura, A. H. Ellebedy, A. H. J. Kim, Effect of Immunosuppression on the
794 Immunogenicity of mRNA Vaccines to SARS-CoV-2. *Ann Intern Med.* 174, M21-1757 (2021).
- 795 23. L. P. M. van Leeuwen, C. H. GeurtsvanKessel, P. M. Ellerbroek, G. J. de Bree, J. Potjewijd,
796 A. Rutgers, H. Jolink, F. van de Veerdonk, E. C. M. van Gorp, F. de Wilt, S. Bogers, L.
797 Gommers, D. Geers, A. H. W. Bruns, H. L. Leavis, J. W. van Haga, B. A. Lemkes, A. van der

- 798 Veen, S. F. J. de Kruijf-Bazen, P. van Paassen, K. de Leeuw, A. A. J. M. van de Ven, P. H.
799 Verbeek-Menken, A. van Wengen, S. M. Arend, A. J. Ruten-Budde, M. W. van der Ent, P. M.
800 van Hagen, R. W. Sanders, M. Grobben, K. van der Straten, J. A. Burger, M. Poniman, S.
801 Nierkens, M. J. van Gils, R. D. de Vries, V. A. S. H. Dalm, Immunogenicity of the mRNA-1273
802 COVID-19 vaccine in adult patients with inborn errors of immunity. *J Allergy Clin Immunol*
803 (2022), doi:10.1016/j.jaci.2022.04.002.
- 804 24. O. Zimmerman, A. M. A. Doss, P. Kaplonek, C.-Y. Liang, L. A. VanBlargan, R. E. Chen, J.
805 M. Monroy, H. J. Wedner, A. Kulczycki, T. L. Mantia, C. C. O’Shaughnessy, H. G. Davis-Adams,
806 H. L. Bertera, L. J. Adams, S. Raju, F. R. Zhao, C. J. Rigell, T. B. Dy, A. L. Kau, Z. Ren, J. S.
807 Turner, J. A. O’Halloran, R. M. Presti, D. H. Fremont, P. L. Kendall, A. H. Ellebedy, G. Alter, M.
808 S. Diamond, mRNA vaccine boosting enhances antibody responses against SARS-CoV-2
809 Omicron variant in individuals with antibody deficiency syndromes. *Cell Reports Medicine*,
810 100653 (2022).
- 811 25. A. Durandy, S. Kracker, A. Fischer, Primary antibody deficiencies. *Nat Rev Immunol.* 13,
812 519–533 (2013).
- 813 26. H. Abolhassani, L. Hammarström, C. Cunningham-Rundles, Current genetic landscape in
814 common variable immune deficiency. *Blood.* 135, 656–667 (2020).
- 815 27. G. de Valles-Ibáñez, A. Esteve-Solé, M. Piquer, E. A. González-Navarro, J. Hernandez-
816 Rodriguez, H. Laayouni, E. González-Roca, A. M. Plaza-Martin, Á. Deyà-Martínez, A. Martín-
817 Nalda, M. Martínez-Gallo, M. García-Prat, L. del Pino-Molina, I. Cuscó, M. Codina-Solà, L.
818 Batlle-Masó, M. Solís-Moruno, T. Marquès-Bonet, E. Bosch, E. López-Granados, J. I. Aróstegui,
819 P. Soler-Palacín, R. Colobran, J. Yagüe, L. Alsina, M. Juan, F. Casals, Evaluating the Genetics
820 of Common Variable Immunodeficiency: Monogenetic Model and Beyond. *Front Immunol.* 9,
821 636 (2018).
- 822 28. D. J. A. Bogaert, M. Dullaers, B. N. Lambrecht, K. Y. Vermaelen, E. D. Baere, F. Haerynck,
823 Genes associated with common variable immunodeficiency: one diagnosis to rule them all? *J*
824 *Med Genet.* 53, 575 (2016).
- 825 29. P. Maffucci, C. A. Filion, B. Boisson, Y. Itan, L. Shang, J.-L. Casanova, C. Cunningham-
826 Rundles, Genetic Diagnosis Using Whole Exome Sequencing in Common Variable
827 Immunodeficiency. *Front Immunol.* 7, 220 (2016).
- 828 30. P. Tuijnenburg, H. L. Allen, S. O. Burns, D. Greene, M. H. Jansen, E. Staples, J. Stephens,
829 K. J. Carss, D. Biasci, H. Baxendale, M. Thomas, A. Chandra, S. Kiani-Alikhan, H. J. Longhurst,
830 S. L. Seneviratne, E. Oksenhendler, I. Simeoni, G. J. de Bree, A. T. J. Tool, E. M. M. van
831 Leeuwen, E. H. T. M. Ebberink, A. B. Meijer, S. Tuna, D. Whitehorn, M. Brown, E. Turro, A. J.
832 Thrasher, K. G. C. Smith, J. E. Thaventhiran, T. W. Kuijpers, Z. Adhya, H. Alachkar, A.
833 Anantharachagan, R. Antrobus, G. Arumugakani, C. Bacchelli, H. Baxendale, C. Bethune, S.
834 Bibi, B. Boardman, C. Booth, M. Browning, M. Brownlie, S. Burns, A. Chandra, H. Clifford, N.
835 Cooper, S. Davies, J. Dempster, L. Devlin, R. Doffinger, E. Drewe, D. Edgar, W. Egner, T. El-
836 Shanawany, B. Gaspar, R. Ghurye, K. Gilmour, S. Goddard, P. Gordins, S. Grigoriadou, S.
837 Hackett, R. Hague, L. Harper, G. Hayman, A. Herwadkar, S. Hughes, A. Huissoon, S. Jolles, J.
838 Jones, P. Kelleher, N. Klein, T. Kuijpers, D. Kumararatne, J. Laffan, H. L. Allen, S. Lear, H.
839 Longhurst, L. Lorenzo, J. Maimaris, A. Manson, E. McDermott, H. Millar, A. Mistry, V. Morrisson,
840 S. Murng, I. Nasir, S. Nejentsev, S. Noorani, E. Oksenhendler, M. Ponsford, W. Qasim, E.

- 841 Quinn, I. Quinti, A. Richter, C. Samarghitean, R. Sargur, S. Savic, S. Seneviratne, C. Sewall, F.
842 Shackley, I. Simeoni, K. G. C. Smith, E. Staples, H. Stauss, C. Steele, J. Thaventhiran, M.
843 Thomas, A. Thrasher, S. Welch, L. Willcocks, S. Workman, A. Worth, N. Yeatman, P. Yong, S.
844 Ashford, J. Bradley, D. Fletcher, T. Hammerton, R. James, N. Kingston, W. Ouwehand, C.
845 Penkett, F. L. Raymond, K. Stirrups, M. Veltman, T. Young, S. Ashford, M. Brown, N. Clements-
846 Brod, J. Davis, E. Dewhurst, M. Erwood, A. Frary, R. Linger, J. Martin, S. Papadia, K.
847 Rehnstrom, W. Astle, A. Attwood, M. Bleda, K. Carss, L. Daugherty, S. Deevi, S. Graf, D.
848 Greene, C. Halmagyi, M. Haimel, F. Hu, R. James, H. L. Allen, V. Matser, S. Meacham, K.
849 Megy, C. Penkett, O. Shamardina, K. Stirrups, C. Titterton, S. Tuna, E. Turro, P. Yu, J. von
850 Ziegenweldt, A. Furnell, R. Mapeta, I. Simeoni, S. Staines, J. Stephens, K. Stirrups, D.
851 Whitehorn, P. Rayner-Matthews, C. Watt, Loss-of-function nuclear factor κ B subunit 1 (NFKB1)
852 variants are the most common monogenic cause of common variable immunodeficiency in
853 Europeans. *J Allergy Clin Immunol.* 142, 1285–1296 (2018).
- 854 31. L. J. Maarschalk-Ellebroek, I. M. Hoepelman, P. M. Ellebroek, Immunoglobulin treatment in
855 primary antibody deficiency. *Int J Antimicrob Ag.* 37, 396–404 (2011).
- 856 32. J. Prevot, S. Jolles, Global immunoglobulin supply: steaming towards the iceberg? *Curr*
857 *Opin Allergy Cl.* 20, 557–564 (2020).
- 858 33. A. L. Miller, N. L. Rider, R. B. Pyles, B. Judy, X. Xie, P.-Y. Shi, T. G. Ksiazek, The arrival of
859 SARS-CoV-2–neutralizing antibodies in a currently available commercial immunoglobulin. *J*
860 *Allergy Clin Immunol.* 149, 1958–1959 (2022).
- 861 34. W. B. Alsoussi, J. S. Turner, J. B. Case, H. Zhao, A. J. Schmitz, J. Q. Zhou, R. E. Chen, T.
862 Lei, A. A. Rizk, K. M. McIntire, E. S. Winkler, J. M. Fox, N. M. Kafai, L. B. Thackray, A. O.
863 Hassan, F. Amanat, F. Krammer, C. T. Watson, S. H. Kleinstein, D. H. Fremont, M. S. Diamond,
864 A. H. Ellebedy, A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection. *J*
865 *Immunol.* 205, j2000583 (2020).
- 866 35. A. O. Hassan, J. B. Case, E. S. Winkler, L. B. Thackray, N. M. Kafai, A. L. Bailey, B. T.
867 McCune, J. M. Fox, R. E. Chen, W. B. Alsoussi, J. S. Turner, A. J. Schmitz, T. Lei, S. Shrihari,
868 S. P. Keeler, D. H. Fremont, S. Greco, P. B. McCray, S. Perlman, M. J. Holtzman, A. H.
869 Ellebedy, M. S. Diamond, A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by
870 Neutralizing Antibodies. *Cell.* 182, 744-753.e4 (2020).
- 871 36. G. E. Weiss, P. D. Crompton, S. Li, L. A. Walsh, S. Moir, B. Traore, K. Kayentao, A.
872 Ongoiba, O. K. Doumbo, S. K. Pierce, Atypical Memory B Cells Are Greatly Expanded in
873 Individuals Living in a Malaria-Endemic Area. *J Immunol.* 183, 2176–2182 (2009).
- 874 37. H. J. Sutton, R. Aye, A. H. Idris, R. Vistein, E. Nduati, O. Kai, J. Mwacharo, X. Li, X. Gao, T.
875 D. Andrews, M. Koutsakos, T. H. O. Nguyen, M. Nekrasov, P. Milburn, A. Eltahla, A. A. Berry,
876 N. KC, S. Chakravarty, B. K. L. Sim, A. K. Wheatley, S. J. Kent, S. L. Hoffman, K. E. Lyke, P.
877 Bejon, F. Luciani, K. Kedzierska, R. A. Seder, F. M. Ndungu, I. A. Cockburn, Atypical B cells are
878 part of an alternative lineage of B cells that participates in responses to vaccination and
879 infection in humans. *Cell Reports.* 34, 108684 (2021).
- 880 38. M.-L. Golinski, M. Demeules, C. Derambure, G. Riou, M. Maho-Vaillant, O. Boyer, P. Joly,
881 S. Calbo, CD11c+ B Cells Are Mainly Memory Cells, Precursors of Antibody Secreting Cells in
882 Healthy Donors. *Front Immunol.* 11, 32 (2020).

- 883 39. H. Rincon-Arevalo, A. Wiedemann, A.-L. Stefanski, M. Lettau, F. Szelinski, S. Fuchs, A. P.
884 Frei, M. Steinberg, T. Kam-Thong, K. Hatje, B. Keller, K. Warnatz, A. Radbruch, A. C. Lino, E.
885 Schrezenmeier, T. Dörner, Deep Phenotyping of CD11c+ B Cells in Systemic Autoimmunity and
886 Controls. *Front Immunol.* 12, 635615 (2021).
- 887 40. S. Shalpour, J. Font-Burgada, G. D. Caro, Z. Zhong, E. Sanchez-Lopez, D. Dhar, G.
888 Willimsky, M. Ammirante, A. Strasner, D. E. Hansel, C. Jamieson, C. J. Kane, T. Klatte, P.
889 Birner, L. Kenner, M. Karin, Immunosuppressive plasma cells impede T-cell-dependent
890 immunogenic chemotherapy. *Nature.* 521, 94–98 (2019).
- 891 41. P. A. Mudd, A. A. Minervina, M. V. Pogorelyy, J. S. Turner, W. Kim, E. Kalaidina, J.
892 Petersen, A. J. Schmitz, T. Lei, A. Haile, A. M. Kirk, R. C. Mettelman, J. C. Crawford, T. H. O.
893 Nguyen, L. C. Rowntree, E. Rosati, K. A. Richards, A. J. Sant, M. K. Klebert, T. Suessen, W. D.
894 Middleton, S. S. Team, J. H. Estep, S. Schultz-Cherry, M. A. McGargill, A. Gaur, J. Hoffman,
895 M. Mori, L. Tang, E. Tuomanen, R. Webby, R. T. Hayden, H. Hakim, D. R. Hijano, K. J. Allison,
896 E. K. Allen, R. Bajracharya, W. Awad, L.-A. V. de Velde, B. L. Clark, T. L. Wilson, A. Souquette,
897 A. Castellaw, R. H. Dallas, A. Gowen, T. P. Fabrizio, C.-Y. Lin, D. C. Brice, S. Cherry, E. K.
898 Roubidoux, V. Cortez, P. Freiden, N. Wohlgemuth, K. Whitt, J. Wolf, S. A. Teefey, J. A.
899 O'Halloran, R. M. Presti, K. Kedzierska, J. Rossjohn, P. G. Thomas, A. H. Ellebedy, SARS-CoV-
900 2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans.
901 *Cell.* 185, 603-613.e15 (2022).
- 902 42. L. Loyal, J. Braun, L. Henze, B. Kruse, M. Dingeldey, U. Reimer, F. Kern, T. Schwarz, M.
903 Mangold, C. Unger, F. Dörfler, S. Kadler, J. Rosowski, K. Gürçan, Z. Uyar-Aydin, M. Frentsch,
904 F. Kurth, K. Schnatbaum, M. Eckey, S. Hippenstiel, A. Hocke, M. A. Müller, B. Sawitzki, S.
905 Miltenyi, F. Paul, M. A. Mall, H. Wenschuh, S. Voigt, C. Drosten, R. Lauster, N. Lachman, L.-E.
906 Sander, V. M. Corman, J. Röhmel, L. Meyer-Arndt, A. Thiel, C. Giesecke-Thiel, Cross-reactive
907 CD4+ T cells enhance SARS-CoV-2 immune responses upon infection and vaccination.
908 *Science.* 374, eabh1823 (2021).
- 909 43. A. G. Dykema, B. Zhang, B. A. Woldemeskel, C. C. Garliss, L. S. Cheung, D. Choudhury, J.
910 Zhang, L. Aparicio, S. Bom, R. Rashid, J. X. Caushi, E. H.-C. Hsiue, K. Cascino, E. A.
911 Thompson, A. K. Kwaa, D. Singh, S. Thapa, A. A. Ordonez, A. Pekosz, F. R. D'Alessio, J. D.
912 Powell, S. Yegnasubramanian, S. Zhou, D. M. Pardoll, H. Ji, A. L. Cox, J. N. Blankson, K. N.
913 Smith, Functional characterization of CD4+ T-cell receptors cross-reactive for SARS-CoV-2 and
914 endemic coronaviruses. *J Clin Invest.* 131 (2021), doi:10.1172/jci146922.
- 915 44. B. J. Laidlaw, A. H. Ellebedy, The germinal centre B cell response to SARS-CoV-2. *Nat Rev*
916 *Immunol.* 22, 7–18 (2022).
- 917 45. R. R. Goel, S. A. Apostolidis, M. M. Painter, D. Mathew, A. Pattekar, O. Kuthuru, S. Gouma,
918 P. Hicks, W. Meng, A. M. Rosenfeld, S. Dysinger, K. A. Lundgreen, L. Kuri-Cervantes, S.
919 Adamski, A. Hicks, S. Korte, D. A. Oldridge, A. E. Baxter, J. R. Giles, M. E. Weirick, C. M.
920 McAllister, J. Dougherty, S. Long, K. D'Andrea, J. T. Hamilton, M. R. Betts, E. T. L. Prak, P.
921 Bates, S. E. Hensley, A. R. Greenplate, E. J. Wherry, Distinct antibody and memory B cell
922 responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination. *Sci*
923 *Immunol.* 6, eabi6950 (2021).
- 924 46. F. Muecksch, Z. Wang, A. Cho, C. Gaebler, T. B. Tanfous, J. DaSilva, E. Bednarski, V.
925 Ramos, S. Zong, B. Johnson, R. Raspe, D. Schaefer-Babajew, I. Shimeliovich, M. Daga, K.-H.

- 926 Yao, F. Schmidt, K. G. Millard, M. Turroja, M. Jankovic, T. Y. Oliveira, A. Gazumyan, M.
927 Caskey, T. Hatzioannou, P. D. Bieniasz, M. C. Nussenzweig, Increased memory B cell potency
928 and breadth after a SARS-CoV-2 mRNA boost. *Nature*, 1–7 (2022).
- 929 47. A. F. Salinas, E. P. Mortari, S. Terreri, C. Quintarelli, F. Pulvirenti, S. D. Cecca, M. Guercio,
930 C. Milito, L. Bonanni, S. Auria, L. Romaggioli, G. Cusano, C. Albano, S. Zaffina, C. F. Perno, G.
931 Spadaro, F. Locatelli, R. Carsetti, I. Quinti, SARS-CoV-2 Vaccine Induced Atypical Immune
932 Responses in Antibody Defects: Everybody Does their Best. *J Clin Immunol.* 41, 1709–1722
933 (2021).
- 934 48. F. Pulvirenti, A. F. Salinas, C. Milito, S. Terreri, E. P. Mortari, C. Quintarelli, S. D. Cecca, G.
935 Lagnese, A. Punziano, M. Guercio, L. Bonanni, S. Auria, F. Villani, C. Albano, F. Locatelli, G.
936 Spadaro, R. Carsetti, I. Quinti, B Cell Response Induced by SARS-CoV-2 Infection Is Boosted
937 by the BNT162b2 Vaccine in Primary Antibody Deficiencies. *Cells.* 10, 2915 (2021).
- 938 49. J. B. Case, S. Mackin, J. Errico, Z. Chong, E. A. Madden, B. Guarino, M. A. Schmid, K.
939 Rosenthal, K. Ren, A. Jung, L. Droit, S. A. Handley, P. J. Halfmann, Y. Kawaoka, J. E. Crowe,
940 D. H. Fremont, H. W. Virgin, Y.-M. Loo, M. T. Esser, L. A. Purcell, D. Corti, M. S. Diamond,
941 *Biorxiv*, in press, doi:10.1101/2022.03.17.484787.
- 942 50. J. S. Turner, J. A. O’Halloran, E. Kalaidina, W. Kim, A. J. Schmitz, J. Q. Zhou, T. Lei, M.
943 Thapa, R. E. Chen, J. B. Case, F. Amanat, A. M. Rauseo, A. Haile, X. Xie, M. K. Klebert, T.
944 Suessen, W. D. Middleton, P.-Y. Shi, F. Krammer, S. A. Teefey, M. S. Diamond, R. M. Presti, A.
945 H. Ellebedy, SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses.
946 *Nature.* 596, 109–113 (2021).